Health Care • Biotechnology: Pharmaceutical Preparations
$7.98 ▼ -0.14
(-1.78%)
MKT CAP: $661.6M • VOL: 1.07M
52W L $3 52W H $15
ROARABLE / RQD
E • 33/100
PIOTROSKI
2 / 9
IMMX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$30.0M | -$22.7M | -$16.1M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$29.4M | -$21.6M | -$15.4M |
| EBITDA (Normalized) | -$29.4M | -$21.7M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$23.9M | -$14.6M | -$11.4M |
| Capital Expenditures (CapEx) | $732.9K | $1.2M | — |
| Free Cash Flow (FCF) | -$24.7M | -$15.8M | -$11.4M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $93.9M | $17.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $93.8M | $13.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR IMMX.